MAP2K6 and colorectal cancer: MAP2K6 was identified as a direct mediator of miR-625-3p associated oxaliplatin resistance in colorectal cancer [69], and it was proposed that miR-625-3p and MAP2K6 could even be used to guide treatment selection [84].